Primary B cell engineering for therapeutic research

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)528-529
Number of pages2
JournalTrends in Molecular Medicine
Issue number6
StatePublished - Jun 2022

Bibliographical note

Funding Information:
Figures were created with, B.S.M. is a founder and equity holder in Bespoke Biotherapeutics LLC. The remaining authors have no interests to declare.


  • B cells
  • gene editing
  • immune cell engineering
  • protein replacement therapy

PubMed: MeSH publication types

  • Journal Article

Cite this